Table 1 Demographic, clinical, and laboratory baseline characteristics of the 75 anti-beta2 glycoprotein I (aβ2GPI) IgG-positive patients and 20 healthy subjects (children)
Primary thrombotic or obstetric APS (n = 34) | SARD (n = 41) | Healthy subjects (n = 20) | |
|---|---|---|---|
Sex, no. (%) female | 31/34 (91%) | 36/41 (88%) | 9/20 (55%) |
Autoimmune disease | 34/34 (100%) | 41/41 (100%) | 0 (0%) |
Primary APS | 34/34 (100%) | 0 (0%) | 0 (0%) |
SLE | 0 (0%) | 11/41 (27%) | 0 (0%) |
SSj | 0 (0%) | 2/41 (5%) | 0 (0%) |
SLE + SSj | 0 (0%) | 3/41 (7%) | 0 (0%) |
DLE | 0 (0%) | 1/41 (2%) | 0 (0%) |
PBC | 0 (0%) | 3/41 (7%) | 0 (0%) |
SSc | 0 (0%) | 2/41 (5%) | 0 (0%) |
DM/PM | 0 (0%) | 4/41 (10%) | 0 (0%) |
UCTD | 0 (0%) | 15/41 (37%) | 0 (0%) |
Thrombosis | 19/34 (56%) | 0 (0%) | 0 (0%) |
Arterial | 7/19 (37%) | 0 (0%) | 0 (0%) |
Venous | 12/19 (63%) | 0 (0%) | 0 (0%) |
Obstetric manifestations | 20/34 (59%) | 0 (0%) | NA |
Pregnancy loss | 15/20 (75%) | 0 (0%) | NA |
Preeclampsia | 5/20 (25%) | 0 (0%) | NA |
Laboratory features | |||
LAC positivity | 24/34 (71%) | 18/41 (44%) | NP |
aβ2GPI IgG, median OD (25–75th percentile) | 1.470 (0.929–1.747) | 1.004 (0.655–1.298) | 0.139 (0.047–0.444) |
aβ2GPI IgM, median OD (25–75th percentile) | 0.350 (0.165–0.576) | 0.450 (0.202–0.838) | 0.088 (0.049–0.132) |